Search

Your search keyword '"van Laarhoven, H.W.M."' showing total 288 results
Start Over Author "van Laarhoven, H.W.M."
288 results on '"van Laarhoven, H.W.M."'

4. Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial)

Author

van de Water, L.F., Kuijper, S.C., Henselmans, I., van Alphen, E.N., Kooij, E.S., Calff, M.M., Beerepoot, L.V., Buijsen, J., Eshuis, W.J., Geijsen, E.D., Havenith, S.H.C., Heesakkers, F.F.B.M., Mook, S., Muller, K., Post, H.C., Rütten, H., Slingerland, M., van Voorthuizen, T., van Laarhoven, H.W.M., and Smets, E.M.A.

Published
2023
Full Text
View/download PDF

9. Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial

Author

de Steur, W.O., van Amelsfoort, R.M., Hartgrink, H.H., Putter, H., Meershoek-Klein Kranenbarg, E., van Grieken, N.C.T., van Sandick, J.W., Claassen, Y.H.M., Braak, J.P.B.M., Jansen, E.P.M., Sikorska, K., van Tinteren, H., Walraven, I., Lind, P., Nordsmark, M., van Berge Henegouwen, M.I., van Laarhoven, H.W.M., Cats, A., Verheij, M., and van de Velde, C.J.H.

Published
2021
Full Text
View/download PDF

14. Patterns of recurrent disease after neoadjuvant chemoradiotherapy and esophageal cancer surgery with curative intent in a tertiary referral center

Author

Schuring, N., primary, Stam, W.T., additional, Plat, V.D., additional, Kalff, M.C., additional, Hulshof, M.C.C.M., additional, van Laarhoven, H.W.M., additional, Derks, S., additional, van der Peet, D.L., additional, van Berge Henegouwen, M.I., additional, Daams, F., additional, and Gisbertz, S.S., additional

Published
2023
Full Text
View/download PDF

23. Long-term quality of life in patients with metastatic esophagogastric cancer receiving first-line systemic therapy

Author

Pape, M., Vissers, P.A.J., Slingerland, M., Mohammad, Nadia Haj, van de Poll-Franse, L.V., Verhoeven, R., van Laarhoven, H.W.M., Pape, M., Vissers, P.A.J., Slingerland, M., Mohammad, Nadia Haj, van de Poll-Franse, L.V., Verhoeven, R., and van Laarhoven, H.W.M.

Abstract

Background Thus far, evidence that quality of life (QoL) remains stable during 1st line systemic therapy of patients with metastatic esophagogastric cancer (mEGC) originates from randomized clinical trials (RCTs). Outcomes from a population-based study provides inside into the effect of systemic therapy on HRQoL in daily clinical practice. The aim of this study was to assess QoL of patients with mEGC at baseline, during 1st line, at progression and after disease progression. Methods Patients diagnosed with mEGC (2014-2020) receiving 1st line systemic therapy registered in the Prospective Observational Cohort study of Oesophageal-gastric cancer Patients (POCOP) were included. QoL was measured with the EORTC QLQ-C30 and -OG25 at baseline, during 1st line therapy, at progression and after disease progression. Results Of the 263 included patients, 123, questionnaires were available at baseline, 161 during 1st line, 77 at progression and 89 after progression. Results of the mixed effect models showed that global health status and four functioning scales deteriorated after progression as compared to baseline. Largest improvements during 1st line treatment were observed for odynophagia (mean change -17.3), anxiety (-14.9), dysphagia (-11.7) and eating restrictions (-11.1). Trouble with taste deteriorated at all three time points. Conclusions In accordance to RCTs, QoL outcomes remained relatively stable or improved during 1st line therapy in patients with esophagogastric cancer. Deterioration of functioning scales were mainly observed after progression.

Published
2023

25. Supplementary Data from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Author

van den Ende, Tom, primary, de Clercq, Nicolien C., primary, van Berge Henegouwen, Mark I., primary, Gisbertz, Suzanne S., primary, Geijsen, E.D., primary, Verhoeven, R.H.A., primary, Meijer, Sybren L., primary, Schokker, Sandor, primary, Dings, M.P.G., primary, Bergman, Jacques J.G.H.M., primary, Haj Mohammad, Nadia, primary, Ruurda, Jelle P., primary, van Hillegersberg, Richard, primary, Mook, Stella, primary, Nieuwdorp, Max, primary, de Gruijl, Tanja D., primary, Soeratram, Tanya T.D., primary, Ylstra, Bauke, primary, van Grieken, Nicole C.T., primary, Bijlsma, Maarten F., primary, Hulshof, Maarten C.C.M., primary, and van Laarhoven, H.W.M., primary

Published
2023
Full Text
View/download PDF

26. Figure from Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma: A Single-arm Phase II Feasibility Trial (PERFECT)

Author

van den Ende, Tom, primary, de Clercq, Nicolien C., primary, van Berge Henegouwen, Mark I., primary, Gisbertz, Suzanne S., primary, Geijsen, E.D., primary, Verhoeven, R.H.A., primary, Meijer, Sybren L., primary, Schokker, Sandor, primary, Dings, M.P.G., primary, Bergman, Jacques J.G.H.M., primary, Haj Mohammad, Nadia, primary, Ruurda, Jelle P., primary, van Hillegersberg, Richard, primary, Mook, Stella, primary, Nieuwdorp, Max, primary, de Gruijl, Tanja D., primary, Soeratram, Tanya T.D., primary, Ylstra, Bauke, primary, van Grieken, Nicole C.T., primary, Bijlsma, Maarten F., primary, Hulshof, Maarten C.C.M., primary, and van Laarhoven, H.W.M., primary

Published
2023
Full Text
View/download PDF

29. Predictive Value of Radiological Response, Pathological Response and Relapse-Free Survival for Overall Survival in Neoadjuvant Immunotherapy Trials: Pooled Analysis of 29 Clinical Trials

Author

Nie, Runcong, primary, Chen, Foping, additional, Provencio, Mariano, additional, Wang, Yun, additional, Ende, Tom van den, additional, van Laarhoven, H.W.M., additional, Yuan, Shu-Qiang, additional, Pless, Miklos, additional, Hayoz, Stefanie, additional, Zhou, Zhiwei, additional, Li, Yuan-Fang, additional, Rothschild, Sacha I., additional, and Cai, Muyan, additional

Published
2023
Full Text
View/download PDF

31. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)

Author

Charehbili, A., van de Ven, S., Smit, V.T.H.B.M., Meershoek-Klein Kranenbarg, E., Hamdy, N.A.T., Putter, H., Heijns, J.B., van Warmerdam, L.J.C., Kessels, L., Dercksen, M., Pepels, M.J., Maartense, E., van Laarhoven, H.W.M., Vriens, B., Wasser, M.N., van Leeuwen-Stok, A.E., Liefers, G.J., van de Velde, C.J.H., Nortier, J.W.R., and Kroep, J.R.

Published
2014
Full Text
View/download PDF

35. Team dynamics and clinician’s experience influence decision-making during Upper-GI multidisciplinary team meetings: A multiple case study

Author

Luijten, J.C.H.B.M., primary, Westerman, M.J., additional, Nieuwenhuijzen, G.A.P., additional, Walraven, J.E.W., additional, Sosef, M.N., additional, Beerepoot, L.V., additional, van Hillegersberg, R., additional, Muller, K., additional, Hoekstra, R., additional, Bergman, J.J.G.H.M., additional, Siersema, P.D., additional, van Laarhoven, H.W.M., additional, Rosman, C., additional, Brom, L., additional, Vissers, P.A.J., additional, and Verhoeven, R.H.A., additional

Published
2022
Full Text
View/download PDF

37. 1260TiP The efficacy of the addition of TRAstuzumab and Pertuzumab to neoadjuvant chemoradiation: A randomized multi-center study in resectable HER2 overexpressing adenocarcinoma of the esophagus or gastroesophageal junction (TRAP-2)

Author

Blangé, D., primary, Hulshof, M.C.C.M., additional, van Berge Henegouwen, M.I., additional, Mostert, B., additional, Slingerland, M., additional, Haj Mohammad, N., additional, Grootscholten, M.C., additional, Creemers, G-J.M., additional, Mekenkamp, L.J.M., additional, Fiets, E., additional, De Haan, J.J., additional, Jeene, P., additional, Rozema, T., additional, Berbee, M., additional, Beeker, A., additional, Beerepoot, L.V., additional, Derks, S., additional, Bijlsma, M.F., additional, van Grieken, N., additional, and van Laarhoven, H.W.M., additional

Published
2022
Full Text
View/download PDF

43. 1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)

Author

Janjigian, Y.Y., van Laarhoven, H.W.M., Rha, S.Y., Kozlov, V., Oh, D-Y., Gravina, A., Rapatoni, L., Shoji, H., Hofheinz, R.D., Chen, L-T., Ford, H.E.R., Chenard-Poirier, M., Raoufmoghaddam, S., Lloyd, C., Zhang, C., Mateo, C., and Lee, J.

Published
2024
Full Text
View/download PDF

44. The fear of cancer recurrence and progression in patients with pancreatic cancer

Author

Pijnappel, E.N., Dijksterhuis, W.P.M., Sprangers, M.A.G., Augustinus, S., De Vos-Geelen, J., de Hingh, I.H.J.T., Molenaar, I.Q., Busch, O.R., Besselink, M.G., Wilmink, J.W., van Laarhoven, H.W.M., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Medische Oncologie (9)

Subjects
OUTCOMES, INSTRUMENT, Pancreatic neoplasms, EORTC QLQ-C30, VALIDATION, Pancreatic ductal adenocarcinoma, Fear of cancer progression, Fear of cancer recurrence, QUALITY-OF-LIFE, PERFORMANCE STATUS, SUPPORT, SURVIVAL, HIGHER-ORDER MODELS, EXPECTATIONS
Abstract

Purpose It is plausible that patients with pancreatic cancer experience fear of tumor recurrence or progression (FOP). The aim of this study was to compare FOP in patients with pancreatic cancer treated with surgical resection, palliative systemic treatment, or best supportive care (BSC) and analyze the association between quality of life (QoL) and FOP and the effect of FOP on overall survival (OS). Methods This study included patients diagnosed with pancreatic cancer between 2015 and 2018, who participated in the Dutch Pancreatic Cancer Project (PACAP). The association between QoL and WOPS was assessed with logistic regression analyses. OS was evaluated using Kaplan-Meier curves with the log-rank tests and multivariable Cox proportional hazard analyses adjusted for clinical covariates and QoL. Results Of 315 included patients, 111 patients underwent surgical resection, 138 received palliative systemic treatment, and 66 received BSC. Patients who underwent surgical resection had significantly lower WOPS scores (i.e., less FOP) at initial diagnosis compared to patients who received palliative systemic treatment or BSC only (P < 0.001). Better QoL was independently associated with the probability of having a low FOP in the BSC (OR 0.95, 95% CI 0.91-0.98) but not in the surgical resection (OR 0.97, 95% CI 0.94-1.01) and palliative systemic treatment groups (OR 0.97, 95% CI 0.94-1.00). The baseline WOPS score was not independently associated with OS in any of the subgroups. Conclusion Given the distress that FOP evokes, FOP should be explicitly addressed by health care providers when guiding pancreatic cancer patients through their treatment trajectory, especially those receiving palliative treatment or BSC.

Published
2022

46. Impact of nationwide centralization of oesophageal, gastric, and pancreatic surgery on travel distance and experienced burden in the Netherlands

Author

Luijten, J.C.H.B.M., primary, Nieuwenhuijzen, G.A.P., additional, Sosef, M.N., additional, de Hingh, I.H.J.T., additional, Rosman, C., additional, Ruurda, J.P., additional, van Duijvendijk, P., additional, Heisterkamp, J., additional, de Steur, W.O., additional, van Laarhoven, H.W.M., additional, Besselink, M.G., additional, Groot Koerkamp, B., additional, van Santvoort, H.C., additional, Lemmens, V.E.P., additional, and Vissers, P.A.J., additional

Published
2022
Full Text
View/download PDF

47. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

Author

Kroese, T.E. van Hillegersberg, R. Schoppmann, S. Deseyne, P.R.A.J. Nafteux, P. Obermannova, R. Nordsmark, M. Pfeiffer, P. Hawkings, M.A. Smyth, E. Markar, S. Hanna, G.B. Cheong, E. Chaudry, A. Elme, A. Adenis, A. Piessen, G. Gani, C. Bruns, C.J. Moehler, M. Liakakos, T. Reynolds, J. Morganti, A. Rosati, R. Castoro, C. D'Ugo, D. Roviello, F. Bencivenga, M. de Manzoni, G. Jeene, P. van Sandick, J.W. Muijs, C. Slingerland, M. Nieuwenhuijzen, G. Wijnhoven, B. Beerepoot, L.V. Kolodziejczyk, P. Polkowski, W.P. Alsina, M. Pera, M. Kanonnikoff, T.F. Nilsson, M. Guckenberger, M. Monig, S. Wagner, D. Wyrwicz, L. Berbee, M. Gockel, I. Lordick, F. Griffiths, E.A. Verheij, M. van Rossum, P.S.N. van Laarhoven, H.W.M. Rosman, C. Rütten, H. Gootjes, E.C. Vonken, F.E.M. van Dieren, J.M. Vollebergh, M.A. van der Sangen, M. Creemers, G.-J. Zander, T. Schlößer, H. Cascinu, S. Mazza, E. Nicoletti, R. Damascelli, A. Slim, N. Passoni, P. Cossu, A. Puccetti, F. Barbieri, L. Fanti, L. Azzolini, F. Ventoruzzo, F. Szczepanik, A. Visa, L. Reig, A. Roques, T. Harrison, M. Ciseł, B. Pikuła, A. Skórzewska, M. Vanommeslaeghe, H. Van Daele, E. Pattyn, P. Geboes, K. Callebout, E. Ribeiro, S. van Duijvendijk, P. Tromp, C. Sosef, M. Warmerdam, F. Heisterkamp, J. Vera, A. Jordá, E. López-Mozos, F. Fernandez-Moreno, M.C. Barrios-Carvajal, M. Huerta, M. de Steur, W. Lips, I. Diez, M. Castro, S. O'Neill, R. Holyoake, D. Hacker, U. Denecke, T. Kuhnt, T. Hoffmeister, A. Kluge, R. Bostel, T. Grimminger, P. Jedlička, V. Křístek, J. Pospíšil, P. Mourregot, A. Maurin, C. Starling, N. Chong, I. OMEC working group

Abstract

Background: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. Objective: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. Material and methods: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (

Published
2022

48. Predictive Value of Radiological Response, Pathological Response and Relapse-Free Survival for Overall Survival in Neoadjuvant Immunotherapy Trials: Meta-Analyses of Individual Patient Data

Author

Nie, Runcong, primary, Chen, Foping, additional, Provencio, Mariano, additional, Wang, Yun, additional, Ende, Tom van den, additional, van Laarhoven, H.W.M., additional, Yuan, Shu-Qiang, additional, Pless, Miklos, additional, Hayoz, Stefanie, additional, Zhou, Zhiwei, additional, Li, Yuan-Fang, additional, Rothschild, Sacha I., additional, and Cai, Muyan, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results